当前位置:网站首页>Watson biological's selling and not selling: it can't stop the drop limit for many times, and Liu Junhui, the second shareholder, defected

Watson biological's selling and not selling: it can't stop the drop limit for many times, and Liu Junhui, the second shareholder, defected

2020-12-07 15:31:27 BEDO Finance

The last few days , Watson biology is once again in the spotlight of the public .

It's going to start with a transfer announcement .12 month 4 Sunday night , Watson bio bulletin says , The proposed 11.4 Billion yuan transferred to Shanghai Zerun Biotechnology Co., Ltd ( Hereinafter referred to as “ Zerun, Shanghai ”)32.6% equity , The transferee is Zibo Yunze venture capital partnership ( Limited partnership )( Hereinafter referred to as “ Zibo Yunze ”) etc. .

 Watson biology for sale or not : They can't stop hitting the limit many times , Liu Junhui, the second shareholder, defected

 

front : sell “ Egg laying chicken ”

Upon completion of the transaction , Shanghai Zerun will no longer be a holding subsidiary of Watson biological . according to the understanding of , Shanghai Zerun is considered to be the key to Watson bio's performance growth in the next two to three years , Its main business research and development two price “HPV The vaccine ”、 Nine price “HPV The vaccine ”( Human papillomavirus vaccine ).

Up to now , Domestic listed HPV There are four vaccines . among , Imports have 3 paragraph , GlaxoSmithKline (GSK) And the bivalent vaccines of mosartan and the four and nine valent vaccines of mosartan . domestic HPV In the vaccine , Wantai biological (603392.SH) It's Xinkening , Has been in 2019 year 12 month 31 It was approved to be listed on the stock market on May 1 .

Except for the Xinkening of Wantai biology , Shanghai Zerun is regarded as the most promising domestic product HPV The second company to go public . Previous 2013 year , Watson biology from Wison ( China ) The investment company bought Shanghai Zerun 40.609% equity , After increasing its capital, it gained control .

2011 year , Shanghai Zerun's second price HPV The vaccine was approved for clinical trials , And in the next year into clinical 1 Phase test .2019 year 3 month , Shanghai Zerun launched another nine price HPV Phase I clinical study of vaccines . According to the introduction , It is located in Yuxi, Yunnan Province HPV The vaccine factory is in 2018 We got the drug production license in 1998 .

This year, 6 month , Watson biology has announced that , Shanghai Zerun's second price HPV Application for new vaccine production has been accepted , Will be wholly owned by Shanghai Zerun subsidiary Yuxi Zerun Biotechnology Co., Ltd ( Hereinafter referred to as “ Yuxi Zerun ”) Carry out industrial production .

 Watson biology for sale or not : They can't stop hitting the limit many times , Liu Junhui, the second shareholder, defected

 

Just as the results are about to be transformed , Watson biology uses a notice , It is planned that “ Egg laying chicken ” Sell out . According to first financial news , In Watson Biology 12 month 5 On the teleconference of June , Some investors question ,“ Zerun products are on the market soon , You can make your own blood , Why sell ?”

And there are investors who say it ,“ Do you treat us stock speculators as idiots ?” meanwhile , There are also investors who say ,“ Do you know that there will be karma when you do things like this ?”、“ Can you change the chairman and management ?”

Watson biological chairman Li Yunchun said , It has been carefully considered , It's good for both listed companies and Shanghai Zerun .“ The company is also a major shareholder , We can get profit sharing from the industrialization and sales side of Shanghai Zerun , The cake is bigger , The holding of listed companies can still get good returns .”

Li Yunchun also said , I hope that through such a move , Open up a space for Shanghai Zerun to develop independently , And said Watson's current main focus is on the development of a new crown vaccine , We are also cooperating with Tsinghua University on adenovirus vector , Limited resources , Not very considerate of the development of Shanghai Zerun .

in : Regulators are quick to focus on 、 Inquiry

What we did with Watson Biology , Both Shenzhen Stock Exchange and Yunnan Securities Regulatory Bureau attach great importance to , And issued a letter of concern 、 A letter of inquiry . among , Yunnan Securities Regulatory Bureau asked it to explain the current equity transfer of Shanghai Zerun 、 Capital increase and debt to equity transactions , Whether it will lead to the liability for breach of contract of relevant agreements signed by the company before .

 Watson biology for sale or not : They can't stop hitting the limit many times , Liu Junhui, the second shareholder, defected

 

According to the announcement , Upon completion of the transaction , Wuxi Xinwo biomedical investment management partnership ( Limited partnership , Hereinafter referred to as Wuxi Xinwo ) Will hold Shanghai Zerun 9.0345% Equity of , And Watson has the latter 44.55% Share . let me put it another way , Watson biological through its indirect shareholding 4.02%.

Regarding this , Yunnan Securities Regulatory Bureau asked Watson bio to explain the decision-making procedures and information disclosure of its investment in Wuxi Xinwo , And Wuxi Xinwo's investment decision-making mechanism and the ownership of actual control right , Whether with Watson biological and its major shareholders 、 The directors, supervisors and senior executives have related relations or other interest arrangements .

The Shenzhen Stock Exchange pays close attention to , Whether the introduction of Zibo Yunze and others as shareholders of Shanghai Zerun can achieve the above-mentioned purpose of helping Shanghai Zerun develop , Is it able to support R & D and production and operation of Shanghai Runze , Zibo Yunze 、 Yongxiu concept consists of strategic investment or specific measures arranged for Shanghai Zerun's next development .

meanwhile , Ask Watson to combine with Shanghai Zerun HPV、 Research and development progress and market prospect of HFMD vaccine , Explain the rationality of the transfer of control right in this transaction , And the basis for determining the proportion of equity transfer , Whether there is interest transfer and other behaviors that damage the interests of listed companies and small and medium-sized investors .

Besides , Watson biology used to 2016 year 3 Monthly issue shares to buy assets and raise matching funds 5.98 One hundred million yuan , Among them, it is used to pay for the R & D project expenses of Shanghai Zerun 18035.39 Ten thousand yuan . Shenzhen Stock Exchange asked Watson biology to explain the way in which the raised funds were invested in Shanghai Zerun and the progress of its use .

after : Trust runs out

Under pressure from all sides ,12 month 7 Morning and morning , Watson bio announced that , The board of directors agreed that the company 2020 The sixth extraordinary general meeting of shareholders cancelled the deliberation 《 Proposal on signing the equity transfer and capital increase agreement of Shanghai Zerun Biotechnology Co., Ltd 》, Shanghai Zerun withdraws its control right .

Watson said in the announcement that , It will still promote the R & D and industrialization process of Shanghai Zerun products , On a broader basis , Formulate and launch the planning plan which is in line with the company's strategy and the long-term development of Shanghai Zerun , Ensure its sustainable development .

Watson says , After the disclosure of relevant resolutions , It is widely concerned by investors , said “ Companies value investor opinion , And actively communicate with investors , In order to listen to the opinions of all parties ”. meanwhile , Watson also apologized to investors in the announcement .

But the market didn't buy it , Watson Biology 12 month 7 Day continued to fall , a sudden turn for the worse , The intraday decline reached 20%, The lowest newspaper 36.53 element , The market value evaporated about 130 One hundred million yuan , During many times touched the limit board . As of press time , Watson has fallen to the limit again , newspaper 36.53 element , Decline is 20.00%, The total market value fell to 563.82 One hundred million yuan .

 Watson biology for sale or not : They can't stop hitting the limit many times , Liu Junhui, the second shareholder, defected

 

For now , Whether it's for sale or not , Watson's trust in the market , It's gone . in fact , Watson lives from 2010 Since it was listed on the Shenzhen Stock Exchange in , Li Yunchun, the founder of the company, has repeatedly reduced his shares in the company , The reduction ratio is close to 17%.

According to Watson biology 2020 Third quarter results , By 2020 year 9 month 30 Japan , Li Yunchun only owns Watson 3.13% shares . Except Li Yunchun , Liu Junhui, its second largest shareholder, and Huang jingcong, the person acting in concert 4 month 9 From to 6 month 23 During the day , Total reduction 24 Time , The share reduction is as high as 1028 Thousands of stocks .

After the reduction , Liu Junhui and Huang Jing, acting in concert, hold Watson biological 9048 Thousands of stocks , Accounted for as 5.2168%. Liu Junhui also said , His / her spouse and his / her have issued a plan to reduce their shareholding in Watson bio , The shareholding ratio will be reduced to 5% following .

 Watson biology for sale or not : They can't stop hitting the limit many times , Liu Junhui, the second shareholder, defected

 

At the same time of reducing Watson bio , Liu Junhui is increasing his competition with Watson —— Conde biological (SZ:300601) Investment . This year, 4 month 29 Japan , Kangtai biological released 《 Report on the issuance of non-public shares 》 Show , Liu Junhui will subscribe for more than 3 A share of 100 million yuan , Proportion exceeding 10%.

版权声明
本文为[BEDO Finance]所创,转载请带上原文链接,感谢
https://chowdera.com/2020/12/20201207152119992p.html